Co-Authors
This is a "connection" page, showing publications co-authored by MICHAEL FRUMOVITZ and AMIR A JAZAERI.
Connection Strength
1.243
-
Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. Oncologist. 2023 07 05; 28(7):618-623.
Score: 0.237
-
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 09; 158(3):570-575.
Score: 0.191
-
Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol. 2018; 9:2102.
Score: 0.170
-
A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
Score: 0.169
-
Potential immunotherapy targets in recurrent cervical cancer. Gynecol Oncol. 2017 06; 145(3):462-468.
Score: 0.152
-
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol. 2023 Feb; 6(1):10-18.
Score: 0.057
-
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Front Oncol. 2022; 12:1001150.
Score: 0.056
-
Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression. Gynecol Oncol. 2022 Dec; 167(3):483-489.
Score: 0.056
-
A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. J Cancer Educ. 2022 06; 37(3):615-620.
Score: 0.055
-
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
Score: 0.052
-
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020 04; 157(1):161-166.
Score: 0.046